Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial

Introduction HIV treatment guidelines now recommend antiretroviral therapy (ART) initiation regardless of CD4 count to maximize benefit both for the individual and society. It is unknown whether the initiation of ART at higher CD4 counts would affect adherence levels. We investigated whether initiat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2018-06, Vol.21 (6), p.e25112-n/a
Main Authors: Iwuji, Collins, McGrath, Nuala, Calmy, Alexandra, Dabis, Francois, Pillay, Deenan, Newell, Marie‐Louise, Baisley, Kathy, Porter, Kholoud
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
adherence
Adult
Africa
AIDS
AIDS treatment
Analysis
Anti-HIV agents
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
antiretroviral therapy
Antiviral agents
Care and treatment
CD4 Lymphocyte Count
Clinics
Diagnosis
Dosage and administration
Drug therapy
Ethics
Female
Funding
Hepatitis, Viral
HIV
HIV infections
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
Human immunodeficiency virus
Humans
Logistic Models
Male
Management
Medication Adherence
Methods
Middle Aged
Patient compliance
pill count
Prospective Studies
South Africa - epidemiology
Studies
test and treat
Testing
virologic suppression
visual analogue scale
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction HIV treatment guidelines now recommend antiretroviral therapy (ART) initiation regardless of CD4 count to maximize benefit both for the individual and society. It is unknown whether the initiation of ART at higher CD4 counts would affect adherence levels. We investigated whether initiating ART at higher CD4 counts was associated with sub‐optimal adherence (
ISSN:1758-2652
1758-2652
DOI:10.1002/jia2.25112